2021高技術發(fā)展報告

目錄
自覺履行高水平科技自立自強的使命擔當（代序）　侯建國　i
前言　中國科學院《高技術發(fā)展報告》課題組　vii
第一章　2020 年高技術發(fā)展綜述　張久春　1
第二章　生物技術新進展　73
2.1　基因編輯技術新進展　李廣磊　黃行許　75
2.2　干細胞與再生醫(yī)學技術新進展　鄭輝　裴端卿　82
2.3　合成生物學技術新進展　陳大明　熊燕　王勇　90
2.4　生物信息技術新進展　李棟　朱云平　賀福初　100
2.5　環(huán)境生物技術新進展　王偉偉　唐鴻志　劉雙江　110
2.6　工業(yè)生物技術新進展　劉龍　劉延峰　陳堅　119
2.7　綠色材料的生物制造技術新進展　陳國強　鄭爽　何宏韜　128
2.8　納米生物技術新進展　陳義祥　張陽　王樹濤　136
2.9　免疫治療技術新進展　于益芝　曹雪濤　144
2.10　病原體防治技術新進展　朱力　王恒樑　陳薇　151
2.11　生物安全技術新進展　王磊　肖堯　武桂珍　161
第三章　生物技術產業(yè)化新進展　171
3.1　疫苗與生物創(chuàng)新藥產業(yè)化新進展　李啟明　173
3.2　現代中藥產業(yè)化新進展　孫曉波　李耿　181
3.3　生物育種技術產業(yè)化新進展　薛勇彪　金京波　程佑發(fā)　王臺　190
3.4　工業(yè)生物制造技術產業(yè)化新進展　汪琪琦　王欽宏　馬延和　198
3.5　生物質能源技術產業(yè)化新進展　孫永明　209
3.6　環(huán)保生物資源挖掘與利用產業(yè)化新進展　王愛杰　黃聰　劉文宗　郜爽　侯雅男　217
3.7　食品生物技術產業(yè)化新進展　劉延峰　陳堅　226
第四章　醫(yī)藥制造業(yè)國際競爭力與創(chuàng)新能力評價　233
4.1　中國醫(yī)藥制造業(yè)國際競爭力評價　郭鑫　藺潔　235
4.2　中國醫(yī)藥制造業(yè)創(chuàng)新能力評價　王孝炯　薛曉宇　259
第五章　高技術與社會　277
5.1　腦機接口技術的倫理挑戰(zhàn)　馬詩雯　周程　279
5.2　實驗空間與有限責任：新興科技的倫理與治理　王大洲　287
5.3　當代新興增強技術及其社會影響　楊慶峰　295
5.4　基因增強技術的倫理擔憂　朱慧玲　304
5.5　跨越邊界：新冠病毒疫苗研發(fā)中的社會協(xié)作　張理茜　杜鵬　311
第六章　專家論壇　319
6.1　關于我國生物信息安全的戰(zhàn)略思考　鮑一明　婁曉敏　肖景發(fā)　章張　趙文明　薛勇彪　321
6.2　傳染病防控領域健康醫(yī)療大數據應用存在的問題及對策建議　劉民　梁萬年　330
6.3　關于我國新冠病毒疫苗發(fā)展的戰(zhàn)略思考　施一　335
6.4　新時期開展科技外交的影響因素和政策建議　羅暉　346
6.5　“十四五”時期促進生物經濟發(fā)展的思考與建議　姜江　352
CONTENTS
Consciously Fulfill the Mission to Achieve Self-Reliance and Self-improvement in High-level Science and Technology　i
Introduction　vii
Chapter 1　Overview of High Technology Development in 2020　1
Chapter 2　Progress in Biotechnology　73
2.1　Gene Editing　75
2.2　Stem Cell and Regenerative Medicine　82
2.3　Synthetic Biology　90
2.4　Bioinformation Technology　100
2.5　Environmental Biotechnology　110
2.6　Industrial Biotechnology　119
2.7　Bioplastics Production Technology　128
2.8　Nano-biotechnology　136
2.9　Immunotherapy　144
2.10　Technologies in the Control and Prevention of Pathogens　151
2.11　Biosafety Technology　161
Chapter 3　Progress in Commercialization of Biotechnology　171
3.1　Commercialization of Vaccine and Bio-innovative Drugs　173
3.2　Commercialization of Modern Chinese Medicine　181
3.3　Commercialization of Biotech Seeds　190
3.4　Commercialization of Industrial Biomanufacturing　198
3.5　Commercialization of Biomass Energy Technologies　209
3.6　Commercialization of the Mining and Utilization in Environmental Biological Resources　217
3.7　Commercialization of Food Biotechnology　226
Chapter 4　Evaluation on Pharmaceutical Industry Competitiveness and Innovation Capacity　233
4.1　Evaluation on International Competitiveness of Chinese Pharmaceutical Industry　235
4.2　Evaluation on Innovation Capacity of Chinese Pharmaceutical Industry　259
Chapter 5　High Technology and Society　277
5.1　Ethical Challenges of Brain-Computer Interface Technology　279
5.2　Experimental Space and Limited Liability：Ethics and Governance of Emerging Science and Technologies　287
5.3　Contemporary Emerging Enhancement Technology and Its Influence　295
5.4　The Moral Concerns of Genetic Enhancement　304
5.5　Social Collaboration in Research and Development（R&D）of COVID-19 Vaccine 311
Chapter 6　Expert Forum　319
6.1　Strategic Thinking on Biological Information Security in China　321
6.2　Problems and Countermeasures in the Application of Healthcare Big Data in Infectious Disease Prevention and Control　330
6.3　Strategic Thinking on the Development of COVID-19 Vaccine in China　335
6.4　Influencing Factors and Policy Suggestions of Developing Science and Technology Diplomacy in the New Era　346
6.5　Thinkings and Recommendations on Promoting the Development of Bioeconomy in the 14th Five Year Plan Period　352